• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

造血细胞因子信号传导中的Janus蛋白酪氨酸激酶

The Janus protein tyrosine kinases in hematopoietic cytokine signaling.

作者信息

Ihle J N

机构信息

Department of Biochemistry, St Jude Children's Research Hospital, Memphis, TN 38101, USA.

出版信息

Semin Immunol. 1995 Aug;7(4):247-54. doi: 10.1006/smim.1995.0029.

DOI:10.1006/smim.1995.0029
PMID:8520029
Abstract

Cytokines regulate cellular functions through their interaction with members of the cytokine receptor superfamily. These receptors couple ligand binding to induction of tyrosine phosphorylation through their association with the Janus protein tyrosine kinases (Jaks). Receptor dimerization induces Jak homo- or hetero-associations, autophosphorylation and activation of Jak catalytic activity. The activated Jaks are hypothesized to phosphorylate the receptors as well as a number of proteins involved in cellular signaling including SHC, the p85 subunit of PI 3-kinase, Vav and members of the Signal Transducers and Activators of Transcription (Stats) family of transcription factors. Receptor phosphorylation also allows association of hematopoietic cell phosphatase with the receptor complex, resulting in its down-regulation. Receptor mutants have allowed the identification of specific domains that are required for each function and their correlation with biological responses.

摘要

细胞因子通过与细胞因子受体超家族成员相互作用来调节细胞功能。这些受体通过与Janus蛋白酪氨酸激酶(Jaks)结合,将配体结合与酪氨酸磷酸化的诱导偶联起来。受体二聚化诱导Jak的同源或异源缔合、自磷酸化以及Jak催化活性的激活。据推测,活化的Jaks会使受体以及许多参与细胞信号传导的蛋白质磷酸化,这些蛋白质包括SHC、PI 3激酶的p85亚基、Vav以及转录因子信号转导和转录激活因子(Stats)家族的成员。受体磷酸化还允许造血细胞磷酸酶与受体复合物结合,从而导致其下调。受体突变体有助于确定每种功能所需的特定结构域及其与生物学反应的相关性。

相似文献

1
The Janus protein tyrosine kinases in hematopoietic cytokine signaling.造血细胞因子信号传导中的Janus蛋白酪氨酸激酶
Semin Immunol. 1995 Aug;7(4):247-54. doi: 10.1006/smim.1995.0029.
2
Jaks and Stats in signaling by the cytokine receptor superfamily.细胞因子受体超家族信号传导中的Jaks和Stats
Trends Genet. 1995 Feb;11(2):69-74. doi: 10.1016/s0168-9525(00)89000-9.
3
Janus kinases in cytokine signalling.细胞因子信号传导中的Janus激酶
Philos Trans R Soc Lond B Biol Sci. 1996 Feb 29;351(1336):159-66. doi: 10.1098/rstb.1996.0012.
4
Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) in hematopoietic cells.造血细胞中的Janus激酶(JAKs)和信号转导及转录激活因子(STATs)
Int J Hematol. 2000 Jun;71(4):309-19.
5
Signaling by the cytokine receptor superfamily: JAKs and STATs.细胞因子受体超家族的信号传导:JAK激酶和信号转导及转录激活因子
Trends Biochem Sci. 1994 May;19(5):222-7. doi: 10.1016/0968-0004(94)90026-4.
6
Cytokine receptor signalling through two novel families of transducer molecules: Janus kinases, and signal transducers and activators of transcription.细胞因子通过两个新型转导分子家族进行信号传导:Janus激酶以及信号转导和转录激活因子。
J Endocrinol. 1995 Oct;147(1):11-23. doi: 10.1677/joe.0.1470011.
7
Signaling through the hematopoietic cytokine receptors.通过造血细胞因子受体的信号传导。
Annu Rev Immunol. 1995;13:369-98. doi: 10.1146/annurev.iy.13.040195.002101.
8
Activation of the JAK-STAT signal transduction pathway by oncostatin-M cultured human and mouse osteoblastic cells.抑瘤素-M对人及小鼠成骨细胞JAK-STAT信号转导通路的激活作用
Endocrinology. 1996 Apr;137(4):1159-65. doi: 10.1210/endo.137.4.8625884.
9
Cytokine signal transduction and the JAK family of protein tyrosine kinases.细胞因子信号转导与蛋白酪氨酸激酶的JAK家族
Bioessays. 1994 May;16(5):313-20. doi: 10.1002/bies.950160505.
10
The Janus kinase family and signaling through members of the cytokine receptor superfamily.Janus激酶家族与通过细胞因子受体超家族成员进行的信号传导。
Proc Soc Exp Biol Med. 1994 Jul;206(3):268-72. doi: 10.3181/00379727-206-43757.

引用本文的文献

1
Discovery of Novel Tofacitinib-ADTOH Molecular Hybridization Derivatives for the Treatment of Ulcerative Colitis.用于治疗溃疡性结肠炎的新型托法替布-ADTOH分子杂交衍生物的发现。
Antioxidants (Basel). 2025 Mar 8;14(3):325. doi: 10.3390/antiox14030325.
2
Discovery of -(4-(Aminomethyl)phenyl)-5-methylpyrimidin-2-amine Derivatives as Potent and Selective JAK2 Inhibitors.发现-(4-(氨甲基)苯基)-5-甲基嘧啶-2-胺衍生物作为强效和选择性JAK2抑制剂
ACS Med Chem Lett. 2023 Aug 1;14(8):1113-1121. doi: 10.1021/acsmedchemlett.3c00251. eCollection 2023 Aug 10.
3
Hydrogen sulfide suppresses HO-induced proliferation and migration of HepG2 cells through Wnt/β-catenin signaling pathway.硫化氢通过 Wnt/β-连环蛋白信号通路抑制 HO 诱导的 HepG2 细胞增殖和迁移。
Med Oncol. 2023 Jun 28;40(8):214. doi: 10.1007/s12032-023-02091-w.
4
Structure-Activity Study of Nitazoxanide Derivatives as Novel STAT3 Pathway Inhibitors.硝唑尼特衍生物作为新型信号转导和转录激活因子3(STAT3)通路抑制剂的构效关系研究
ACS Med Chem Lett. 2021 Apr 1;12(5):696-703. doi: 10.1021/acsmedchemlett.0c00544. eCollection 2021 May 13.
5
Inhibition of USP9X Downregulates JAK2-V617F and Induces Apoptosis Synergistically with BH3 Mimetics Preferentially in Ruxolitinib-Persistent JAK2-V617F-Positive Leukemic Cells.USP9X的抑制作用下调JAK2-V617F并与BH3模拟物协同诱导凋亡,在鲁索替尼耐药的JAK2-V617F阳性白血病细胞中表现尤为明显。
Cancers (Basel). 2020 Feb 10;12(2):406. doi: 10.3390/cancers12020406.
6
Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia.接受 fedratinib 治疗的骨髓纤维化、真性红细胞增多症和原发性血小板增多症患者的群体药代动力学。
Cancer Chemother Pharmacol. 2019 Oct;84(4):891-898. doi: 10.1007/s00280-019-03929-9. Epub 2019 Aug 23.
7
Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?靶向治疗急性髓系白血病的酪氨酸激酶:为何、针对谁及如何治疗?
Int J Mol Sci. 2019 Jul 12;20(14):3429. doi: 10.3390/ijms20143429.
8
JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.用于治疗骨髓增殖性肿瘤和其他疾病的JAK抑制剂。
F1000Res. 2018 Jan 17;7:82. doi: 10.12688/f1000research.13167.1. eCollection 2018.
9
Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome.人类酪氨酸激酶2缺乏症:无高免疫球蛋白E综合征的分枝杆菌和病毒感染。
J Exp Med. 2015 Sep 21;212(10):1641-62. doi: 10.1084/jem.20140280. Epub 2015 Aug 24.
10
Erythropoietin in stroke therapy: friend or foe.促红细胞生成素在中风治疗中的作用:是友还是敌。
Curr Med Chem. 2015;22(10):1205-13. doi: 10.2174/0929867322666150114152134.